Prince Pharmaceutical Co., Ltd.
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufena… Read more
Prince Pharmaceutical Co., Ltd. (6935) - Total Liabilities
Latest total liabilities as of June 2025: NT$618.16 Million TWD
Based on the latest financial reports, Prince Pharmaceutical Co., Ltd. (6935) has total liabilities worth NT$618.16 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Prince Pharmaceutical Co., Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Prince Pharmaceutical Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Prince Pharmaceutical Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Prince Pharmaceutical Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alton Sports Co.Ltd
KQ:123750
|
Korea | ₩10.70 Billion |
|
Peace & Living PCL
BK:PEACE
|
Thailand | ฿1.73 Billion |
|
Replenish Nutrients Holding Corp.
F:7KE
|
Germany | €11.61 Million |
|
TWL Holdings Bhd
KLSE:7079
|
Malaysia | RM172.79 Million |
|
TVI Pacific Inc
PINK:TVIPF
|
USA | $5.81 Million |
|
Barrister Energy LLC
PINK:CJAX
|
USA | $589.86K |
|
Choice Development Inc
TW:9929
|
Taiwan | NT$998.37 Million |
|
Inswave Systems Co., Ltd.
KQ:450520
|
Korea | ₩13.48 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Prince Pharmaceutical Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prince Pharmaceutical Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prince Pharmaceutical Co., Ltd. (2019–2024)
The table below shows the annual total liabilities of Prince Pharmaceutical Co., Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$626.19 Million | -1.62% |
| 2023-12-31 | NT$636.47 Million | -1.46% |
| 2022-12-31 | NT$645.91 Million | -6.09% |
| 2021-12-31 | NT$687.77 Million | +13.85% |
| 2020-12-31 | NT$604.10 Million | +12.52% |
| 2019-12-31 | NT$536.89 Million | -- |